News Releases

DEER PARK, Ill. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday,

- Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide - Application is Eton’s Sixth Drug Application Under FDA Review DEER PARK, Ill.

-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of Methanol Poisoning -DS-100 is Eton’s Fifth Drug Application Under FDA Review and Second Orphan Application

DEER PARK, Ill. , May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an update on

- Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product - Eton plans to file Post Grant Reviews in the U.S. Patent & Trademark Office challenging the validity of Exela’s listed patents, which, if successful, could allow Eton to launch in 2021 - Eton believes Exela Pharma

DEER PARK, Ill. , May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May

Orphan Drug Expert Paul Stickler to Lead Eton’s Commercialization of Alkindi® Sprinkle and Pediatric Neurology Franchise DEER PARK, Ill. , May 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing

-Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan Drug Designation for Adrenal Insufficiency in Pediatric Patients -Eton Executed $7.8 Million Equity

-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill. , March 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused

DEER PARK, Ill. , March 05, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the fourth quarter ended December 31, 2019 and provided an